Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents
Lapochkin OL, Zykov VP, Zavadenko NN, Goryunov AV, Chutko LS, Barhatova AN, Koren EV, Kupriyanova TA, Skoromets AP, Grechany SV, Nesterovsky YE, Goryunova AV, Komarova IB, Barkhatov MV, Sulimov AV, Tsotsonava ZM, Makarov IV · 2026 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 126(9. Vyp. 2)
Published 2026-10-22. Indexed 2026-10-24.
Reported findings and study design
The expert council places Cortexin, Cerebrolysin and Semax in Group B, its category for preparations with a limited evidence base in ADHD. It discusses adjunctive use within psychoeducation and behavioral care, rather than replacement of established first-line treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin, Cerebrolysin and Semax | Group B: limited evidence base for ADHD | |
| Document type | Expert-council resolution | Council meeting 16 July 2026; publication 22 October 2026 |
Expert consensus and evidence appraisal, not a new efficacy trial. The assessment concerns childhood ADHD, not every clinical use of these preparations.
Source for the extracted data ↗ · Checked 2026-10-31
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Expert consensus and evidence appraisal, not a new efficacy trial. The assessment concerns childhood ADHD, not every clinical use of these preparations.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Indexed abstract checked
Source access and review scope
Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred. Publisher page confirms online publication 2026-10-22.
Recorded source-check date: 2026-10-31. This date does not imply a completed systematic review.
Source type: Expert-council resolution
Citation and original source
Original source: Lapochkin OL, Zykov VP, Zavadenko NN, Goryunov AV, Chutko LS, Barhatova AN, Koren EV, Kupriyanova TA, Skoromets AP, Grechany SV, Nesterovsky YE, Goryunova AV, Komarova IB, Barkhatov MV, Sulimov AV, Tsotsonava ZM, Makarov IV. Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 126(9. Vyp. 2) 2026.
Molekul research summary: https://molekul.io/research/oct31-42910684. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Cortexin
A tissue-derived preparation with Russian stroke, cognitive, pediatric and other clinical reports. Study designs vary; the independent stroke review is shown alongside favorable original reports. None validates the personal WHOOP diary.
Semax
ACTH-fragment-derived peptide with clinical stroke and optic-nerve reports, healthy-volunteer imaging and preclinical neuroregulation research. Precursor, patent and dissertation sources remain separately labeled.
Cerebrolysin
Porcine brain-derived peptide mixture studied in neurological disease, rehabilitation and laboratory models. Clinical results, composition analyses and unresolved archival leads are separated in this collection.